Cerebrolysin for early rehabilitation after acute ischemic stroke
Effect of Cerebrolysin on Early Rehabilitation After Ischemic Stroke at the Department of Vascular Neurology and Intensive Neurological Therapy (KOVNINT), University Medical Centre Ljubljana
This trial tests whether adding Cerebrolysin to standard early rehabilitation helps people with moderate acute ischemic stroke recover arm and overall function faster.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Medical Centre Ljubljana Academic / other |
| Locations | 1 site (Ljubljana) |
| Trial ID | NCT07043686 on ClinicalTrials.gov |
What this trial studies
This interventional study at UMC Ljubljana compares patients receiving Cerebrolysin plus standard acute care and early neurorehabilitation to a control group receiving standard care alone. Eligible participants have imaging-confirmed acute ischemic stroke with moderate deficits (NIHSS 6–12) and must be able to perform the Action Research Arm Test (ARAT). Cerebrolysin is a low-molecular-weight peptide preparation derived from porcine brain given as an adjunct during the early rehabilitation period, and the trial tracks motor recovery and safety outcomes. Clinical measures and adverse events are recorded and compared between groups to determine whether Cerebrolysin adds benefit to routine rehabilitation.
Who should consider this trial
Good fit: Ideal candidates are patients with recent imaging-confirmed acute ischemic stroke, NIHSS 6–12, no prior disability (pre-stroke mRS 0), able to perform the ARAT, and who provide informed consent.
Not a fit: Patients with minor strokes, prior stroke-related disability, inability to follow instructions or perform the ARAT, or non-ischemic stroke types are unlikely to benefit from this protocol.
Why it matters
Potential benefit: If successful, adding Cerebrolysin could improve motor recovery and functional outcomes during early post-stroke rehabilitation.
How similar studies have performed: Cerebrolysin has been used in multiple prior trials and some meta-analyses report modest benefits for stroke recovery, but overall results across studies are mixed and not definitive.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Being able to perform ARAT test Signed informed consent Both sexes, age not specified Acute ischemic stroke confirmed by imaging NIHSS score 6-12 No prior stroke or disability (mRS 0 before stroke) \- Exclusion Criteria: Not being able to perform ARAT test * Previous stroke or disability (mRS \> 0) * The patient unable to understand instructions
Where this trial is running
Ljubljana
- UMC Ljubljana - Department of Vascular Neurology and Intensive Neurological Therapy (KOVNINT) — Ljubljana, Slovenia (Recruiting)
Study contacts
- Principal investigator: Matija Zupan, MD, PhD — University Medical Centre Ljubljana
- Study coordinator: Matija Zupan, MD, PhD
- Email: matija.zupan@kclj.si
- Phone: 0038615229581
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.